Fellowships

WAHTN is committed to supporting translational health and medical research in WA. This ensures research outcomes are translated into changes in policy, practice and innovation to benefit the health and well-being of all Australians. To support the next generation of translational health researchers, we have introduced our Fellowship programs to foster career development and support WA translational projects.

Early Career Fellowships in Translational Health Research

In 2019, 11 leading Western Australian early career researchers were awarded a 12 month WAHTN Early Career Fellowship to support WA research and translation projects. This program was supported in part by $1 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) with matched funding from the Fellow’s affiliated organisation.

The Fellowships were awarded to:

  • Research-focused clinicians and health care professionals with less than 10 years post primary degree or within 5 years of a postgraduate degree, with consideration for career breaks, with emphasis placed on supporting Allied Health, Biostatisticians and Health Economists.
  • Projects that demonstrated collaboration, community and consumer involvement, aligned with MRFF priority areas and improved health care, health systems, health policy and/or public health.

Fellows were provided salary support for a part-time or full-time position and were paired with a mentor from the WAHTN Management Committee to guide, support, connect and enhance their experience throughout the year.

Statements from Fellows

This Fellowship has “provided me with the opportunity to fully focus on my research and to deliver on the first ever analysis of the national Familial Hypercholesterolaemia (FH) registry data”. It has also “allowed me to form new partnerships with implementation researchers to take my research findings to the next step of actual implementation, and to close the identified healthcare gaps in FH.” (Dr Jing Pang)

“The appreciation that I have further developed for cancer patients and their families during this fellowship has been quite profound. The value of bench to bedside should not be underestimated, and in fact perhaps be extended to bench to bedside and back again. It is imperative that scientists understand the rigorous testing that cancer patients undergo and fully adopt consumer engagement in the research setting. Without the commitment of patients, the value of our research cannot be fully realised. I would like to take this opportunity that thank the patients and their families that were involved in this project, and the WAHTN for allowing me to conduct this research.” (Dr Ashleigh McEvoy)

“I would like to express my sincere thanks and gratitude for the opportunities that have arisen as a recipient of the WAHTN Early Careers Fellowship in Translational Research. Through this fellowship, I was able to focus full-time on my research, as opposed to conducting research on top of my workload responsibilities. As a result, and with the support of my research team, we have been able to generate data that has the capacity to positively influence the lives of young infants with Cerebral Palsy who are experiencing communication impairment. I have also benefited from the mentorship program” … “worked to build my research profile, networks and research outputs” … and it “has enabled me to demonstrate emerging leadership on grant applications.” (Dr Roslyn Ward)

“This fellowship and mentorship program enabled me to demonstrate my ability to lead large scale implementation research. I gained invaluable experience in leading a research team, working across health services and navigating multiple research ethics and governance processes. The project enabled me to strengthen collaborative relationships with key stakeholders in health services, organisations and consumer groups. I anticipate that the opportunities provided during the fellowship and mentorship will be a strong foundation to build on for future partnership research.” (Dr Fenella Gill)

2019 Fellowship Recipients

NamePositionOrganisationProject TitleGrantPublication Summary
Dr Gail AlvaresPostdoctoral Research FellowTelethon Kids InstituteEstablishing an autism phenomics platform for Western Australia$112,107Autism spectrum disorder is a neurodevelopmental condition that impacts brain development, diagnosed in more than 1% of the population. A diagnosis is currently based solely on behavioural symptoms emerging in early childhood. However, the underlying biological mechanisms contributing to a diagnosis remain unknown. One such mechanism may be differences in the metabolome, or the collection of small-molecule chemicals called metabolites. To conduct such research, very large and well-characterised sample cohorts are required, particularly in complex and heterogeneous conditions like autism. This project aimed to explore the metabolic differences from urine and blood samples of a large cohort of children with autism, to provide a first step towards establishing a phenomics analysis platform for autism research. To further our understanding of metabolic differences in children on the autism spectrum, this project conducted a large scoping review, implicating several metabolites that differ between children with and without an autism diagnosis. The findings from this research are now being used to inform analytical strategies for investigating urine samples of children on the autism spectrum, their siblings, and unrelated children from the general community. This project is contributing to a broader research program into understanding more effective and personalised therapies for children on the autism spectrum towards better health outcomes.
Ms Jodie ArmstrongOccupational Therapist & PhD CandidateCurtin UniversityThe Learn, Engage and Play (LEaP) Study: The Development and Evaluation of a Therapeutic Playgroup for Children with Developmental Delay$90,962The Learn, Engage and Play (LEaP) study developed and evaluated the effectiveness of a therapeutic playgroup for children with developmental delays when first referred to an early intervention service. This consumer driven study arose from parents’ desire to have a way of accessing information early to support their child’s development and connect with other families experiencing the same challenges. Embedded into the Child Development Service of Western Australia and supported by Curtin University, Western Australian Health Translation Network (WAHTN), Collaborate for Kids (CoLab) and the Perth Children’s Hospital Foundation; this study collaborated with over 150 consumers, policy‐makers, practitioners and community members during the planning, development, and evaluation of the LEaP playgroup. Study findings indicated the LEaP playgroup was highly valued by families and positively improved child outcomes and levels of family support. In a research environment characterised by inconsistent playgroup definitions and models, this study created new playgroup knowledge, clarifying therapeutic playgroup practice principles and producing the first evidence‐based and empirically tested manualised therapeutic playgroup for young children with significant developmental delays. It also demonstrates how academic institutions and health services can partner to address consumer identified needs and develop evidence‐based interventions that can be translated into practice.
Dr Fenella GillAssociate Professor Acute Paediatric NursingCurtin UniversityUnifying systems for recognition and response to paediatric clinical deterioration in Western Australia$114,601Failure to detect and act on signs of clinical deterioration in a timely manner can result in serious adverse outcomes with devastating results, particularly in children. In WA, there is not a uniform approach to recognising and responding to clinical deterioration for hospitalised children and this may contribute in failure to recognise or respond in a timely manner to critical changes in a child’s condition. The Project aimed to develop an evidence based state-wide system for recognising and responding to clinical deterioration in WA paediatric settings inclusive of family participation and to evaluate the feasibility and factors necessary to ensure successful implementation. The project was successful in developing and trialling a proposed uniform ESCALATION System that was a product of widespread stakeholder and consumer input and review. This system is unique in incorporating a chart - PARROT, a framework for escalation communication and integrated parent concern. At the six pilot sites (PCH, Fiona Stanley Hospital, Joondalup Health Campus, Narrogin Hospital, Albany Hospital and Broome Hospital) the trial system was well received by staff and families, with feedback provided to further fine tune prior to full implementation. Final testing is now underway at two sites (PCH and Broome Hospital) prior to state-wide implementation planned for 2021.
Dr Ariel MaceGeneral Paediatric ConsultantPerth Children's HospitalFeBRILe3 – Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months old$58,860
Dr Luke MarinovichResearch FellowCurtin UniversityImpact of consensus guidelines on margins for breast conserving surgery: translation to clinical care in WA$70,743
Dr Ashleigh McEvoyPost-Doctoral Research Fellow & Clinical CoordinatorEdith Cowan UniversityTranslation of “Liquid Biopsy” Research into Clinical Practice$95,000The highly aggressive nature of metastatic melanoma demands that we maximise opportunities to intervene with optimal treatment at the earliest time. Currently radiological imaging remains the gold standard for determining treatment response or disease progression, however are typically performed 3-12 monthly. Apart from the high costs and radiation exposure, the time differences may allow the disease to manifest and remain undetected. Circulating tumour DNA {ctDNA) (released from tumour cells into blood), is a valuable tool for measuring disease change in melanoma and we have previously shown a strong correlation between ctDNA and PET-derived metabolic tumour burden (MTB) in a cohort of treatment na'ive metastatic melanoma patients. The utility of serial ctDNA monitoring has not been well documented and as such, we sought to evaluate if ctDNA can predict treatment response or progressive disease in metastatic melanoma patients undergoing active treatment or surveillance. Our study provides some key insights into ctDNA assessment suggesting that with current testing procedures, clinical value is only realised in a subset of patients. Consequently, further improvements in the detection and quantification of ctDNA would be required before it can be effectively translated into the clinic.
Ms Belinda McLeanPostdoctoral Research FellowCurtin UniversityImplementation of an evidence-based allied health intervention to improve functional outcomes of children with cerebral palsy$70,632
Dr Jing PangResearch FellowThe University of Western AustraliaTranslational research for improving the care of familial hypercholesterolaemia: closing the gaps$117,720 "Familial" means it runs in families and "hypercholesterolaemia" means high blood cholesterol. Familial Hypercholesterolaemia (FH) is the most common and serious form of inherited high cholesterol. People with FH are at an increased risk of developing cardiovascular disease. Practical research on prevention strategies can improve cardiovascular health outcomes and lower the burden of health costs. Using data from a national registry, the current project has identified healthcare gaps in the detection and management of FH in Australia. FH patients are diagnosed later in life and often do not achieve adequate cholesterol lowering despite a high frequency of cardiovascular disease and risk factors. The project highlighted the need for earlier diagnosis of FH and earlier initiation of cholesterol-lowering therapy, as well as more comprehensive management of cardiovascular risk factors.
Dr Janessa PickeringSenior Research FellowTelethon Kids InstituteDeveloping laboratory diagnostics for Strep A carriage: an essential step to progress vaccine and acute rheumatic fever primary prevention$94,163Group A Streptococcus bacteria (Streptococcus pyogenes, Strep A) cause superficial and invasive infections (e.g. sore throat, skin infection, blood infection), the complications of which include acute rheumatic fever and rheumatic heart disease. These diseases of poverty are responsible for significant morbidity and mortality, manifesting in the marginalised populations of the world including Aboriginal and Torres Strait Islander children. Effective prevention strategies (including vaccines) are urgently needed to alleviate the burden from this priority population in Australia. As vaccine candidates progress through the development pipeline, epidemiological surveillance data will facilitate decision-making for the Strep A vaccine targets, vaccine efficacy and implementation strategies. Strep A surveillance is a developing but necessary tool for reducing the burden of Strep A disease. To improve Strep A surveillance, this project has determined the optimal way to store and handle throat swabs collected from children. Our new methods can be applied in low- and high- resource settings to measure the rates of Strep A infection and the impact of preventative measures including health policies and vaccinations. Novel application of a phage-lysin to disrupt Strep A cell walls has also led to optimised DNA extraction protocols which are now being utilised in surveillance studies in Australia.
Dr Roslyn WardSenior Research FellowCurtin UniversityB2: I Can Communicate$117,720It is reported 60-85% of children with Cerebral Palsy (CP), have communication problems, with 1 in 4 children unable to talk. Early diagnosis is therefore critical to minimising the cascading consequences of communication impairment. The “B2: I Can Communicate” project evaluated the developmental profile of early vocalisations/speech/language development of infants with/at risk of CP representing the first longitudinal study. Eighteen children with CP and 18 typically developing (TD) children were followed at 3 monthly intervals from 6 months to 18 months of age. Researchers, clinicians and stakeholders were involved throughout the project; with recommended changes in clinician practice and clinical pathways evaluated. Data analyses show significant group differences in both the type of infant vocalisations and developmental trajectory of early speech/language development. TD children displayed an increasing developmental trajectory over time, whilst the trajectory of development for CP was decreasing, indicating increasing communication impairment compared to TD children. A clinical audit, undertaken to assess implementation and translation into clinical practice, shows a significant decrease in the age at which children were assessed, and change in assessment practices. This project contributes to a data-driven knowledge base for clinicians in the early diagnosis and management of communication disorders associated with CP and focuses on building clinical care pathways.
Dr Yue WuPostdoctoral Research OfficerTelethon Kids InstituteProspective evaluation of a clinical decision-support tool to guide antibiotic selection for empiric treatment of urinary infections in children$57,670